🇺🇸 FDA

Company profile · Sponsor

Sarepta

Sarepta Therapeutics

SRPT · NYSE pharma CAMBRIDGE, MA, USA
Pipeline
24
Drugs
3
Patents
8

Quick answer

Sarepta (SRPT) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker SRPT
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0000873303

Pipeline (24)

Search pipeline →

  1. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  2. Casimersen

    Sarepta

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  3. Delandistrogene moxeparvovec-rokl

    Sarepta

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  4. ETEPLIRSEN (AVI-4658)

    Sarepta

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  5. Eteplirsen

    Sarepta

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  6. PREDNISONE, SRP-9003, PREDNISONE, PREDNISONE

    Sarepta

    Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy

    phase 3 small molecule active

    1 trial

  7. SRP-4045

    Sarepta

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    2 trials

  8. SRP-9003

    Sarepta

    Limb-girdle Muscular Dystrophy

    phase 3 mab active

    2 trials

  9. SRP-9005

    Sarepta

    Muscular Dystrophies, Limb-Girdle

    phase 3 mab terminated

    1 trial

  10. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  11. delandistrogene moxeparvovec

    Sarepta

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    7 trials

  12. eteplirsen

    Sarepta

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule completed

    2 trials

  13. AVI-4065 Injection

    Sarepta

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  14. AVI-4658 (Eteplirsen)

    Sarepta

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  15. AVI-4658 (Eteplirsen)

    Sarepta

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule completed

    1 trial

  16. AVI-4658 (PMO)

    Sarepta

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  17. AVI-4658 for Injection

    Sarepta

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  18. AVI-5126

    Sarepta

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  19. Amondys 45

    Sarepta

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  20. Eteplirsen

    Sarepta

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  21. Placebo

    Sarepta

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  22. Placebo - Sodium Chloride 9 mg/ml (0.9%) - Solution for injection, ARO-DM1

    Sarepta

    Type 1 Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  23. RESTEN-MP

    Sarepta

    Coronary Artery Disease

    phase 2 small molecule completed

    2 trials

  24. SODIUM CHLORIDE, ARO-DUX4

    Sarepta

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

Drugs (3)

Search drugs →

  1. casimersen

    AMONDYS 45

    INTRAVENOUS approved

  2. eteplirsen

    EXONDYS

    INTRAVENOUS approved

    M09AX

  3. golodirsen

    VYONDYS 53

    INTRAVENOUS approved

Patents (8)

Search patents →

  1. US 12377150

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12370261

    Chimeric peptides for antisense delivery

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12286630

    Treatment methods for muscular dystrophy

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12239715

    Peptide oligonucleotide conjugates

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12168059

    Trimeric peptides for antisense delivery

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12138312

    Cell-penetrating peptides for antisense delivery

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12139709

    Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12121532

    Modified antisense oligomers for exon inclusion in spinal muscular atrophy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Sarepta?

Sarepta (SRPT) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does Sarepta sponsor?

We track 24 ClinicalTrials.gov-linked programs for Sarepta, including CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Sarepta company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.